[go: up one dir, main page]

DK0930883T3 - Neurotrofinantagonister til behandling af epilepsi, Alzheimers sygdom og smerte - Google Patents

Neurotrofinantagonister til behandling af epilepsi, Alzheimers sygdom og smerte

Info

Publication number
DK0930883T3
DK0930883T3 DK97909098T DK97909098T DK0930883T3 DK 0930883 T3 DK0930883 T3 DK 0930883T3 DK 97909098 T DK97909098 T DK 97909098T DK 97909098 T DK97909098 T DK 97909098T DK 0930883 T3 DK0930883 T3 DK 0930883T3
Authority
DK
Denmark
Prior art keywords
loweralkyl
neurotrophin
carboxy
optionally substituted
epilepsy
Prior art date
Application number
DK97909098T
Other languages
English (en)
Inventor
Ashok Tehim
Xiannong Chen
Original Assignee
Nps Allelix Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9621902.7A external-priority patent/GB9621902D0/en
Priority claimed from GBGB9710904.5A external-priority patent/GB9710904D0/en
Application filed by Nps Allelix Corp filed Critical Nps Allelix Corp
Application granted granted Critical
Publication of DK0930883T3 publication Critical patent/DK0930883T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D221/00Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04Ortho- or peri-condensed ring systems
    • C07D221/06Ring systems of three rings
    • C07D221/14Aza-phenalenes, e.g. 1,8-naphthalimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/473Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK97909098T 1996-10-21 1997-10-20 Neurotrofinantagonister til behandling af epilepsi, Alzheimers sygdom og smerte DK0930883T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9621902.7A GB9621902D0 (en) 1996-10-21 1996-10-21 Neurotrophin antagonist compositions
GBGB9710904.5A GB9710904D0 (en) 1997-05-27 1997-05-27 Neurotropin antagonist compositions

Publications (1)

Publication Number Publication Date
DK0930883T3 true DK0930883T3 (da) 2006-05-22

Family

ID=26310264

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97909098T DK0930883T3 (da) 1996-10-21 1997-10-20 Neurotrofinantagonister til behandling af epilepsi, Alzheimers sygdom og smerte

Country Status (14)

Country Link
US (4) US20020169182A1 (da)
EP (1) EP0930883B1 (da)
JP (1) JP2001503397A (da)
KR (1) KR20000052691A (da)
AT (1) ATE315397T1 (da)
AU (1) AU728523C (da)
BR (1) BR9712424A (da)
CA (1) CA2268450C (da)
DE (1) DE69735090T2 (da)
DK (1) DK0930883T3 (da)
ES (1) ES2257768T3 (da)
IL (1) IL129475A0 (da)
NZ (1) NZ335291A (da)
WO (1) WO1998017278A1 (da)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0930883T3 (da) 1996-10-21 2006-05-22 Nps Allelix Corp Neurotrofinantagonister til behandling af epilepsi, Alzheimers sygdom og smerte
JP2002530379A (ja) * 1998-11-25 2002-09-17 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 置換ベンゾ[de]イソキノリン−1,3−ジオン類
WO2000032577A2 (en) * 1998-11-25 2000-06-08 Merck Patent Gmbh Substituted benzo[de]isoquinoline-1,3-diones
US6492380B1 (en) * 1999-05-17 2002-12-10 Queen's University At Kingston Method of inhibiting neurotrophin-receptor binding
US6468990B1 (en) 1999-05-17 2002-10-22 Queen's University At Kingston Method of inhibiting binding of nerve growth factor to p75 NTR receptor
FR2807660A1 (fr) * 2000-04-13 2001-10-19 Warner Lambert Co Utilisation d'antagonistes du ngf pour la prevention ou le traitement de douleurs viscerales chroniques
WO2005000194A2 (en) 2002-10-08 2005-01-06 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
EP1556083B1 (en) 2002-10-08 2011-02-02 Rinat Neuroscience Corp. Methods for treating post-surgical pain by admisnistering an antibody against nerve growth factor and compositions containing the same
CA2921578C (en) 2002-12-24 2017-02-14 Rinat Neuroscience Corp. Anti-ngf antibodies and methods using same
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
EP2191846A1 (en) 2003-02-19 2010-06-02 Rinat Neuroscience Corp. Method for treating pain by administering a nerve growth factor antagonist and an NSAID and composition containing the same
FR2862967B1 (fr) * 2003-12-01 2006-08-04 Sanofi Synthelabo Derives de (4-phenylpiperazin-1-yl)acylpiperidine, leur preparation et leur application en therapeutique
FR2862968B1 (fr) * 2003-12-01 2006-08-04 Sanofi Synthelabo Derives de 4-[(arylmethyl)aminomethyl]piperidine, leur preparation et leur application en therapeutique
KR101504729B1 (ko) 2004-04-07 2015-03-19 리나트 뉴로사이언스 코프. 신경성장인자 길항제의 투여에 의한 골암 통증 치료용 약학적 조성물
GB0419850D0 (en) * 2004-09-07 2004-10-13 Angeletti P Ist Richerche Bio Therapeutic agents
JP2009507861A (ja) * 2005-09-15 2009-02-26 ペインセプター ファーマ コーポレーション ニューロトロフィン媒介性活性を調節する方法
WO2009039635A1 (en) * 2007-09-24 2009-04-02 Painceptor Pharma Corporation Methods of modulating neurotrophin-mediated activity
FR2953839A1 (fr) 2009-12-14 2011-06-17 Sanofi Aventis Nouveaux derives d'(heterocycle-piperidine condensee)-(piperazinyl)-1alcanone ou d'(heterocycle-pyrrolidine condensee)-(piperazinyl)-1alcanone et leur utilisation comme inhibiteurs de p75
SI3333188T1 (sl) 2010-08-19 2022-04-29 Zoetis Belgium S.A. Protitelesa proti NGF in njihova uporaba
EP2606894A1 (en) 2011-12-20 2013-06-26 Sanofi Novel therapeutic use of p75 receptor antagonists
JP6629069B2 (ja) 2012-06-06 2020-01-15 ゾエティス・エルエルシー イヌ化抗ngf抗体およびその方法
CN111819197B (zh) 2018-03-12 2025-03-11 硕腾服务有限责任公司 抗ngf抗体及其方法
EP4185567A4 (en) * 2020-07-24 2024-08-14 Jawaharlal Nehru Centre For Advanced Scientific Research NAPHTHALENE MONOIMIDE COMPOUNDS AND RELATED METHODS
WO2023212596A1 (en) 2022-04-27 2023-11-02 Regeneron Pharmaceuticals, Inc. Treatment of arthropathy based upon stratification of osteoarthritis polygenic risk score
US20240310383A1 (en) 2023-03-17 2024-09-19 Regeneron Pharmaceuticals, Inc. Proteomic Risk Score For Osteoarthritis (OA)

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US525841A (en) * 1894-09-11 Baling-press
US627129A (en) * 1899-06-20 Collar-edge-ironing machine
US3821383A (en) * 1972-07-10 1974-06-28 Ayerst Mckenna & Harrison Compositions for and a method of treating diabetic complications
US4006238A (en) * 1975-08-28 1977-02-01 E. R. Squibb & Sons, Inc. Use of 2-(hydroxyalkyl)-1H-benz[de]isoquinoline-1,3(2H)-diones as anti-allergy agents
ES459497A1 (es) * 1977-06-04 1978-04-16 Made Labor Sa Un metodo para la preparacion industrial de naftalimidas y sus derivados.
US4254109A (en) * 1979-11-08 1981-03-03 Ayerst, Mckenna & Harrison Inc. 1H-Benz[de]isoquinoline-2(3H)-acetic acid derivatives
RU2051677C1 (ru) * 1982-02-10 1996-01-10 Украинский научно-исследовательский институт эндокринологии и обмена веществ Средство для профилактики и лечения диабетических осложнений, ангиопатий, нейропатий, катаракты
US5183821A (en) * 1983-09-19 1993-02-02 Laboratories Knoll, S.A. Method for treating leukemias using N-(2-dimethylaminoethyl)-3-amino-1,8-naphthalimide for treating leukemias and solid tumors
IT1214618B (it) * 1985-06-27 1990-01-18 I P A International Pharmaceut Composti e composizioni farmaceutiche per la terapia di retinopatie e neuropatie diabetiche.
DE3635711A1 (de) * 1986-10-21 1988-04-28 Knoll Ag 5-nitrobenzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung
DE3707651A1 (de) * 1987-03-10 1988-09-22 Knoll Ag Bis-naphthalimide, ihre herstellung und verwendung
DE3707652A1 (de) * 1987-03-10 1988-09-22 Knoll Ag Verwendung von benzo(de)isochinolin-1,3-dionen zur herstellung von arzneimitteln
US5420137A (en) * 1989-07-11 1995-05-30 Knoll Ag Amonafide salts
US5356906A (en) * 1989-10-27 1994-10-18 The Du Pont Merck Pharmaceutical Company (N-phthalimidoalkyl) piperidines useful as treatments for psychosis
CA2030129A1 (en) * 1989-11-29 1991-05-30 Thomas Saupe 1,8-napthalenedicarboximides as antidotes
US5342942A (en) * 1992-06-09 1994-08-30 Warner-Lambert Company Pyrazoloquinazolone derivatives as neurotrophic agents
DE4232739A1 (de) * 1992-09-30 1994-03-31 Knoll Ag Neue asymmetrisch substituierte bis-Naphthalimide
IL110460A (en) * 1993-08-18 2001-01-11 Basf Ag Bis-naphthalimides, their preparation and pharmaceutical compositions containing them
US6291247B1 (en) * 1994-05-11 2001-09-18 Queen's University At Kingston Methods of screening for factors that disrupt neurotrophin conformation and reduce neurotrophin biological activity
GB9616105D0 (en) * 1996-07-31 1996-09-11 Univ Kingston TrkA binding site of NGF
DK0930883T3 (da) 1996-10-21 2006-05-22 Nps Allelix Corp Neurotrofinantagonister til behandling af epilepsi, Alzheimers sygdom og smerte
ES2297909T3 (es) 1997-02-07 2008-05-01 Emisphere Technologies, Inc. Compuestos y composiciones para el suministro de agentes activos.
WO1998052919A1 (fr) 1997-05-21 1998-11-26 Japan Tobacco Inc. Derives de phtalimide et produit pharmaceutique contenant ces derives
AU4698299A (en) 1998-06-30 2000-01-17 Du Pont Pharmaceuticals Company 5-HT7 receptor antagonists
AU727591B2 (en) * 1998-07-03 2000-12-14 Taiho Pharmaceutical Co., Ltd. Naphthalimidobenzamide derivatives
US6468990B1 (en) * 1999-05-17 2002-10-22 Queen's University At Kingston Method of inhibiting binding of nerve growth factor to p75 NTR receptor
US6492380B1 (en) * 1999-05-17 2002-12-10 Queen's University At Kingston Method of inhibiting neurotrophin-receptor binding

Also Published As

Publication number Publication date
IL129475A0 (en) 2000-02-29
ATE315397T1 (de) 2006-02-15
NZ335291A (en) 2001-02-23
CA2268450C (en) 2008-08-05
AU4696897A (en) 1998-05-15
BR9712424A (pt) 2001-11-20
US20020169182A1 (en) 2002-11-14
US20080287484A1 (en) 2008-11-20
DE69735090T2 (de) 2006-09-14
ES2257768T3 (es) 2006-08-01
JP2001503397A (ja) 2001-03-13
AU728523B2 (en) 2001-01-11
KR20000052691A (ko) 2000-08-25
AU728523C (en) 2001-08-09
WO1998017278A1 (en) 1998-04-30
DE69735090D1 (de) 2006-04-06
US20090215815A1 (en) 2009-08-27
US20050250807A1 (en) 2005-11-10
CA2268450A1 (en) 1998-04-30
EP0930883A1 (en) 1999-07-28
US7291629B2 (en) 2007-11-06
EP0930883B1 (en) 2006-01-11

Similar Documents

Publication Publication Date Title
DK0930883T3 (da) Neurotrofinantagonister til behandling af epilepsi, Alzheimers sygdom og smerte
HK1094191A1 (en) Phenyl-carboxamide compounds useful for treating pain
DE69531502D1 (de) Monoamid, diamid, thiol enthaltende metall-chelatierende verbindungen
DK0652005T3 (da) Fremgangsmåder til inhibering af endometriose
MX9709416A (es) Compuesto tipo quinolizinona.
IL129238A0 (en) N-(aryl/heteroarylacetyl) amino acid esters pharmaceutical compositions comprising same and methods for inhibiting b-amyloid peptide release and/ or its synthesis by use of such compounds
MY135057A (en) Dolastatin 15 derivatives
WO1998046576A3 (en) Halo-alkoxycarbonyl prodrugs
DK0652002T3 (da) Anvendelse af 2-phenyl-3-aroylebenzothiophener til fremstilling af et medikament til hæmning af brusknedbrydning
DK0659427T3 (da) 2-Phenyl-3-azoylbenzothiophener til forøgelse af thrombomodulinekspression
YU69699A (sh) Derivati aril karbonske kiseline i tetrazola
DK0659414T3 (da) Inhibering af hirutisme og alopeci hos kvinder
DE69810332D1 (de) Antibakterielle carbapeneme, zusammensetzungen und verfahren zur behandlung
AU5270696A (en) Novel heterocyclic compounds
DE69622393D1 (de) Neue verwendung von pyrazolopyridinverbindungen
MX9701528A (es) Derivados de 1, 1, 2,- trifenilbut-1-eno para tratar la enfermedad de alzheimer.
MX9703610A (es) Nuevas (5,6)-heteroaril condensado-pirimidin-4-onas 2,3 disustituidas.